Johnson & Johnson Services Inc acquires Shockwave Medical

Johnson & Johnson has announced the acquisition of Shockwave Medical for approximately $13.1 billion, a move enhancing its capabilities in the cardiovascular market. The transaction brings Shockwave's intravascular lithotripsy (IVL) technology into Johnson & Johnson's MedTech division, significantly bolstering its offerings in treating coronary artery disease (CAD) and peripheral artery disease (PAD). These areas are known for their complexity in cardiac intervention, where advanced solutions are in high demand.

The acquisition integrates Shockwave’s IVL technology, which uses sonic pressure waves to break down calcified arterial plaque, with Johnson & Johnson’s established cardiovascular product line. This approach aims to improve interventional cardiology outcomes by offering minimally invasive treatment options. Johnson & Johnson’s CEO, Joaquin Duato, underscored the alignment of this acquisition with the company’s mission to tackle cardiovascular disease, a significant health challenge globally. Tim Schmid, Executive Vice President and Worldwide Chairman of Johnson & Johnson MedTech, highlighted the transaction's potential to expand the company's reach in complex interventions and anticipated a surge in innovative outcomes globally.

For Shockwave, the acquisition by Johnson & Johnson presents an opportunity to integrate its pioneering IVL technology with the larger company's expansive resources, including global distribution networks and research capabilities. Doug Godshall, President and CEO of Shockwave Medical, remarked on the potential for accelerated adoption of IVL as a standard of care, capitalizing on Johnson & Johnson's scale to make such therapies more widely accessible.

This acquisition aligns with Johnson & Johnson's strategic pivot following its consumer health division spin-off, enhancing its focus on innovative medicines and medical technology. By integrating Shockwave’s offerings, Johnson & Johnson intensifies its commitment to high-growth healthcare segments, leveraging its size and resources to drive advancements in minimally invasive cardiac care. The deal positions Johnson & Johnson to compete robustly in a market characterized by rapid technological advancements and growing demand for modern procedural solutions.

Looking forward, Johnson & Johnson anticipates that Shockwave's IVL platform will significantly contribute to MedTech's revenue and influence across new geographies and clinical environments. The company's investment in ongoing research and development underscores its commitment to evolving catheter-based and cardiovascular solutions. With the acquisition completed, Johnson & Johnson solidifies its foothold in the fast-paced cardiovascular sector, aiming to deliver superior patient outcomes and sustain shareholder value through targeted innovation and expanded market accessibility.